All In Biotech

Drug Trial Radar · NCT05307874

Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors

A Two-part, Open-label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 in Combination With Low-dose Subcutaneous Interleukin-2 in Patients With Advanced Solid Tumors (EVICTION-2)

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

56

Actual

Start

May 4, 2022

Primary completion

Oct 9, 2025

Study completion Oct 9, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/IIa, two-part, open-label study to characterize the safety, tolerability, pharmacodynamics, and antitumor activity of ICT01 in combination with LDSC IL-2 in patients with advanced-stage solid tumors. Part 1 will be a dose escalation of IV ICT01 administered on the first day of every 21-day cycle (CnD1) to patients with advanced-stage solid tumors in combination with LDSC IL-2 (Proleukin®) administered daily on days 1-5 of cycles 1-3 (C1-3D1-5). Objectives of part 1 are to characterize the safety of the combination regimen and determine the RP2D for Part 2. Part 2 will comprise a maximum of 2 indications and 2 combination dosing regimens of ICT01 +LDSC IL-2, which will be supported by statistical power calculations once the indications are selected. The final regimen will be ICT01 + LDSC IL-2 + Pembrolizumab on a Q3W cycle. The primary objective of Part 2 is to demonstrate the efficacy of the combination regimen based on RECIST1.1 in one or more solid tumor indications.

Conditions

  • Solid Tumor, Adult

Interventions

  • ICT01Drug

    anti-BTN3A mAb IV Q3W

  • Proleukin Injectable ProductDrug

    1 MIU/m2 SC IL-2 daily x 5 days for the first 3 cycles

  • Pembrolizumab injectionDrug

    200mg administered following ICT01 + LDSC IL-2 over 30 min Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-Emergent Adverse EventsTime frame: 1 year

Locations

5 sites in 3 countries. Site status is shown where the registry gives one.

  • Institute Gustave Roussy

    Paris, France

  • IUCT Oncopole Claudius Regaud

    Toulouse, France

  • University Carl Gustav Carus

    Dresden, Germany

  • Universitätsklinikum Wuerzburg

    Würzburg, Germany

  • The Institute of Cancer Research

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.